title: [Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
abstract: OBJECTIVE
  We retrospectively analyzed comparative toxicities and efficacies of chemotherapy regimens in advanced gastric cancer (AGC) patients who achieved complete response (CR) after chemotherapy.
  
  
  METHODS
  We reviewed the medical records of 1,203 patients, who were pathologically diagnosed as AGC in a single center between January 2001 and October 2007. On the basis of the Response Evaluation Criteria in Solid Tumors, CR was evaluated with abdominal computed tomography. Toxicities were evaluated using the National Cancer Institute's common toxicity criteria before each chemotherapy cycle.
  
  
  RESULTS
  Among the 1,203 AGC patients enrolled in this study, 568 received chemotherapy and 635 received best supportive care. The major chemotherapy regimens were 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), docetaxel, cisplatin and 5-fluorouracil (DCF) and 5-fluorouracil, leucovorin and irinotecan (FOLFIRI). Among the 568 patients, 51 (9.0%) achieved CR (49 [8.6%] with FOLFOX [n=12], DCF [n=26], or FOLFIRI [n=11] and 2 [0.3%] with etoposide, leucovorin and 5-fluorouracil). For patients administered FOLFOX, DCF, and FOLFIRI, the median time to disease progression was 4 months (range, 1.8-59.5), 15 months (range, 2.9-31.2) and 10 months (range, 2.0-39.5), and the median survival times were 48 months (range, 5.9-74.0), 37 months (range, 14.0-86.0), and 30 months (range, 6.0-50.0), respectively. Grades 3-4 mucositis occurred mostly in patients administered DCF (n=8, 30.8%). Grades 3-4 leucopenia were observed in 1 (8.3%), 11 (42.3%), and 4 (36.4%) patients administered FOLFOX, DCF and FOLFIRI, respectively. No statistically significant differences were observed in the 3 regimens.
  
  
  CONCLUSIONS
  All 3 regimens (FOLFOX, DCF and FOLFIRI) were active and tolerable. Their efficacies and toxicities were not significantly different.
authors.affiliation: Department of Internal Medicine, Chungnam National University, School of Medicine, Daejeon, Korea.
authors.forename: Yun Jeung
authors.initials: YJ
authors.lastname: Kim
authors.forename: Pyung Gohn
authors.initials: PG
authors.lastname: Goh
authors.forename: Eui Sik
authors.initials: ES
authors.lastname: Kim
authors.forename: Su Youn
authors.initials: SY
authors.lastname: Lee
authors.forename: Hee Seok
authors.initials: HS
authors.lastname: Moon
authors.forename: Eaum Seok
authors.initials: ES
authors.lastname: Lee
authors.forename: Jae Kyu
authors.initials: JK
authors.lastname: Sung
authors.forename: Seok Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Byung Seok
authors.initials: BS
authors.lastname: Lee
authors.forename: Hyun Yong
authors.initials: HY
authors.lastname: Jeong
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use / Q000633:toxicity; D002945:Cisplatin / Q000627:therapeutic use / Q000633:toxicity; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use / Q000633:toxicity; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000209:etiology; D009325:Nausea / Q000209:etiology; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use / Q000633:toxicity; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality; D015996:Survival Rate; D043823:Taxoids / Q000627:therapeutic use / Q000633:toxicity; D014057:Tomography, X-Ray Computed; D014839:Vomiting / Q000209:etiology
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D043823:Taxoids; D000077143:Docetaxel; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin